Tzen CY, Mau BL, Hsu HJ. Analysis of disease-associated ND4 mutations: how do we know which mutation is pathogenic? Mitochondrion. 2007;7(1–2):151–6.

Article  CAS  PubMed  Google Scholar 

Rodenburg RJ. Mitochondrial complex I-linked disease. Biochim Biophys Acta. 2016;1857(7):938–45.

Article  CAS  PubMed  Google Scholar 

Dulski J, Uitti RJ, Ross OA, Wszolek ZK. Genetic architecture of Parkinson’s disease subtypes - review of the literature. Front Aging Neurosci. 2022;14:1023574.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bose A, Beal MF. Mitochondrial dysfunction in Parkinson’s disease. J Neurochem. 2016;139(Suppl 1):216–31.

Article  CAS  PubMed  Google Scholar 

Choong CJ, Mochizuki H. Gene therapy targeting mitochondrial pathway in Parkinson’s disease. J Neural Transm (Vienna). 2017;124(2):193–207.

Article  CAS  PubMed  Google Scholar 

Drouin-Ouellet J. Mitochondrial complex I deficiency and Parkinson disease. Nat Rev Neurosci. 2023.

Vos M. Mitochondrial complex I deficiency: guilty in Parkinson’s disease. Signal Transduct Target Ther. 2022;7(1):136.

Article  PubMed  PubMed Central  Google Scholar 

Gonzalez-Rodriguez P, Zampese E, Stout KA, Guzman JN, Ilijic E, Yang B, et al. Disruption of mitochondrial complex I induces progressive parkinsonism. Nature. 2021;599(7886):650–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kösel S, Hofhaus G, Maassen A, Vieregge P, Graeber MB. Role of mitochondria in Parkinson disease. Biol Chem. 1999;380(7–8):865–70.

PubMed  Google Scholar 

Prasuhn J, Bruggemann N. Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson’s Disease. Genes (Basel). 2021;12(11).

Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587):979–80.

Article  CAS  PubMed  Google Scholar 

Top 25 NeuroRehabilitation articles. NeuroRehabilitation. 2017;40(1):9–10.

Article  Google Scholar 

San Miguel M, Martin KL, Stone J, Johnstone DM. Photobiomodulation mitigates Cerebrovascular Leakage Induced by the Parkinsonian Neurotoxin MPTP. Biomolecules. 2019;9(10).

Dionisio PA, Amaral JD, Rodrigues CMP. Oxidative stress and regulated cell death in Parkinson’s disease. Ageing Res Rev. 2021;67:101263.

Article  CAS  PubMed  Google Scholar 

Santidrian AF, Matsuno-Yagi A, Ritland M, Seo BB, LeBoeuf SE, Gay LJ, et al. Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. J Clin Invest. 2013;123(3):1068–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bordt EA, Clerc P, Roelofs BA, Saladino AJ, Tretter L, Adam-Vizi V, et al. The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species. Dev Cell. 2017;40(6):583–e946.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan W, Chen J, Cao Y, Yang L, Shen L, Bian Q, et al. Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene. J Gene Med. 2018;20(7–8):e3027.

Article  PubMed  Google Scholar 

Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, et al. Glucocerebrosidase gene therapy prevents alpha-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015;82:495–503.

Article  CAS  PubMed  Google Scholar 

Morganti JM, Nash KR, Grimmig BA, Ranjit S, Small B, Bickford PC, et al. The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson’s disease. J Neurosci. 2012;32(42):14592–601.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang J, Sun B, Yang J, Chen Z, Li Z, Zhang N et al. Comparison of the effect of rotenone and 1–methyl–4–phenyl–1,2,3,6–tetrahydropyridine on inducing chronic Parkinson’s disease in mouse models. Mol Med Rep. 2022;25(3).

Bhurtel S, Katila N, Srivastav S, Neupane S, Choi DY. Mechanistic comparison between MPTP and rotenone neurotoxicity in mice. Neurotoxicology. 2019;71:113–21.

Article  CAS  PubMed  Google Scholar 

Balke D, Tatenhorst L, Dambeck V, Ribas VT, Vahsen BF, Michel U, et al. AAV-Mediated expression of Dominant-negative ULK1 increases neuronal survival and enhances Motor Performance in the MPTP Mouse Model of Parkinson’s Disease. Mol Neurobiol. 2020;57(2):685–97.

Article  CAS  PubMed  Google Scholar 

Shen J, Zha Q, Yang QH, Zhou YQ, Liang X, Chen YJ et al. Inhibiting Von Hippel–Lindau protein-mediated dishevelled ubiquitination protects against experimental parkinsonism. Acta Pharmacol Sin. 2022.

Tesseur I, Nguyen A, Chang B, Li L, Woodling NS, Wyss-Coray T, et al. Deficiency in neuronal TGF-beta signaling leads to Nigrostriatal Degeneration and activation of TGF-beta signaling protects against MPTP Neurotoxicity in mice. J Neurosci. 2017;37(17):4584–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barber-Singh J, Seo BB, Matsuno-Yagi A, Yagi T. Protective role of rAAV-NDI1, serotype 5, in an Acute MPTP Mouse Parkinson’s model. Parkinsons Dis. 2010;2011:438370.

PubMed  PubMed Central  Google Scholar 

Barber-Singh J, Seo BB, Nakamaru-Ogiso E, Lau YS, Matsuno-Yagi A, Yagi T. Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder. Rejuvenation Res. 2009;12(4):259–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seo BB, Nakamaru-Ogiso E, Flotte TR, Matsuno-Yagi A, Yagi T. In vivo complementation of complex I by the yeast Ndi1 enzyme. Possible application for treatment of Parkinson disease. J Biol Chem. 2006;281(20):14250–5.

Article  CAS  PubMed  Google Scholar 

Christine CW, Richardson RM, Van Laar AD, Thompson ME, Fine EM, Khwaja OS, et al. Safety of AADC Gene Therapy for moderately Advanced Parkinson Disease: three-year outcomes from the PD-1101 Trial. Neurology. 2022;98(1):e40–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ge G, Chen C, Guderyon MJ, Liu J, He Z, Yu Y, et al. Regulatable Lentiviral hematopoietic stem cell gene therapy in a mouse model of Parkinson’s Disease. Stem Cells Dev. 2018;27(14):995–1005.

Article  CAS  PubMed  Google Scholar 

Muñoz MF, Argüelles S, Medina R, Cano M, Ayala A. Adipose-derived stem cells decreased microglia activation and protected dopaminergic loss in rat lipopolysaccharide model. J Cell Physiol. 2019;234(8):13762–72.

Article  PubMed  Google Scholar 

Buttery PC, Barker RA. Gene and cell-based therapies for Parkinson’s Disease. Where Are We? Neurother. 2020;17(4):1539–62.

Article  Google Scholar 

Jamebozorgi K, Taghizadeh E, Rostami D, Pormasoumi H, Barreto GE, Hayat SMG, et al. Cellular and Molecular aspects of Parkinson Treatment: future therapeutic perspectives. Mol Neurobiol. 2019;56(7):4799–811.

Article  CAS  PubMed  Google Scholar 

Lin JY, Xie CL, Zhang SF, Yuan W, Liu ZG. Current experimental studies of Gene Therapy in Parkinson’s Disease. Front Aging Neurosci. 2017;9:126.

Article  PubMed  PubMed Central  Google Scholar 

Pandey SK, Singh RK. Recent developments in nucleic acid-based therapies for Parkinson’s disease: current status, clinical potential, and future strategies. Front Pharmacol. 2022;13:986668.

Article  CAS  PubMed  PubMed Central  Google Scholar 

El Ganainy SO, Cijsouw T, Ali MA, Schoch S, Hanafy AS. Stereotaxic-assisted gene therapy in Alzheimer’s and Parkinson’s diseases: therapeutic potentials and clinical frontiers. Expert Rev Neurother. 2022;22(4):319–35.

Article  PubMed  Google Scholar 

Valdés P, Schneider BL. Gene therapy: a Promising Approach for Neuroprotection in Parkinson’s Disease? Front Neuroanat. 2016;10:123.

Article  PubMed  PubMed Central  Google Scholar 

Nam Y, Moon GJ, Kim SR. Therapeutic potential of AAV1-Rheb(S16H) transduction against neurodegenerative diseases. Int J Mol Sci. 2021;22(6).

Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, Kells AP, et al. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson’s disease. Ann Neurol. 2019;85(5):704–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciesielska A, Samaranch L, San Sebastian W, Dickson DW, Goldman S, Forsayeth J, et al. Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial. PLoS ONE. 2017;12(2):e0169965.

Article  PubMed  PubMed Central  Google Scholar 

Van Laar AD, Van Laar VS, San Sebastian W, Merola A, Elder JB, Lonser RR, et al. An update on Gene Therapy approaches for Parkinson’s Disease: restoration of dopaminergic function. J Parkinsons Dis. 2021;11(s2):S173–82.

Article  PubMed  PubMed Central  Google Scholar 

Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, et al. Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease. JCI Insight. 2017;2(7):e90133.

Article  PubMed